Limits...
Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy.

Choi CH, Song SY, Choi JJ, Park YA, Kang H, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS - BMC Cancer (2008)

Bottom Line: Fifteen (51.7%) of 29 patients were scored as VEGF-positive.With logistic regression analysis, VEGF positivity continued to be an independent predictor for poor response (P = 0.032).In addition, the progression-free survival rate was significantly lower in patients with VEGF-positive tumors (P = 0.033).

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Chelhun.choi@samsung.com

ABSTRACT

Background: The prediction of response to treatment would be valuable for managing cervical carcinoma with neoadjuvant chemotherapy.

Methods: To this end, the expression of VEGF was analyzed by immunohistochemistry using paraffin-embedded pre-treatment cervical biopsy tissues. This study included 29 patients with bulky IB to IIA cervical squamous cell carcinoma treated with neoadjuvant chemotherapy.

Results: Fifteen (51.7%) of 29 patients were scored as VEGF-positive. Response to chemotherapy (complete response or residual tumor with less than 3 mm stromal invasion) was observed in eight patients (27.6%), and it was negatively associated with VEGF expression (P = 0.009). With logistic regression analysis, VEGF positivity continued to be an independent predictor for poor response (P = 0.032). In addition, the progression-free survival rate was significantly lower in patients with VEGF-positive tumors (P = 0.033).

Conclusion: Pretreatment assessment of VEGF expression may provide additional information for identification of patients with cervical cancer who had a low likelihood of response to neoadjuvant chemotherapy and an unfavorable prognosis.

Show MeSH

Related in: MedlinePlus

Disease-free survival curve as a function of pathologic response (A) and immunoreactivity to VEGF (B). The P-values were determined using the log-rank test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2572070&req=5

Figure 2: Disease-free survival curve as a function of pathologic response (A) and immunoreactivity to VEGF (B). The P-values were determined using the log-rank test.

Mentions: With a median follow-up period of 48 months (range, 3 to 105), three (10.3%) of 29 patients died of disease and recurrence occurred in seven (24.1%). The overall 5-year disease-free survival rate was higher in the responder group than the non-responder group (100% vs. 65%), although this difference was not statistically significant (P = 0.07) (Figure 2A). The progression-free survival rate was significantly lower in patients with VEGF-positive tumors (vs. VEGF-negative tumors, P = 0.033) (Table 3 and Figure 2B). VEGF-positivity was identified as an independent predictor of patient disease-free survival using a Cox regression model (P = 0.037; hazards ratio, 11.4; 95% CI, 1.15 – 112.58) (Table 3).


Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy.

Choi CH, Song SY, Choi JJ, Park YA, Kang H, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS - BMC Cancer (2008)

Disease-free survival curve as a function of pathologic response (A) and immunoreactivity to VEGF (B). The P-values were determined using the log-rank test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2572070&req=5

Figure 2: Disease-free survival curve as a function of pathologic response (A) and immunoreactivity to VEGF (B). The P-values were determined using the log-rank test.
Mentions: With a median follow-up period of 48 months (range, 3 to 105), three (10.3%) of 29 patients died of disease and recurrence occurred in seven (24.1%). The overall 5-year disease-free survival rate was higher in the responder group than the non-responder group (100% vs. 65%), although this difference was not statistically significant (P = 0.07) (Figure 2A). The progression-free survival rate was significantly lower in patients with VEGF-positive tumors (vs. VEGF-negative tumors, P = 0.033) (Table 3 and Figure 2B). VEGF-positivity was identified as an independent predictor of patient disease-free survival using a Cox regression model (P = 0.037; hazards ratio, 11.4; 95% CI, 1.15 – 112.58) (Table 3).

Bottom Line: Fifteen (51.7%) of 29 patients were scored as VEGF-positive.With logistic regression analysis, VEGF positivity continued to be an independent predictor for poor response (P = 0.032).In addition, the progression-free survival rate was significantly lower in patients with VEGF-positive tumors (P = 0.033).

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Chelhun.choi@samsung.com

ABSTRACT

Background: The prediction of response to treatment would be valuable for managing cervical carcinoma with neoadjuvant chemotherapy.

Methods: To this end, the expression of VEGF was analyzed by immunohistochemistry using paraffin-embedded pre-treatment cervical biopsy tissues. This study included 29 patients with bulky IB to IIA cervical squamous cell carcinoma treated with neoadjuvant chemotherapy.

Results: Fifteen (51.7%) of 29 patients were scored as VEGF-positive. Response to chemotherapy (complete response or residual tumor with less than 3 mm stromal invasion) was observed in eight patients (27.6%), and it was negatively associated with VEGF expression (P = 0.009). With logistic regression analysis, VEGF positivity continued to be an independent predictor for poor response (P = 0.032). In addition, the progression-free survival rate was significantly lower in patients with VEGF-positive tumors (P = 0.033).

Conclusion: Pretreatment assessment of VEGF expression may provide additional information for identification of patients with cervical cancer who had a low likelihood of response to neoadjuvant chemotherapy and an unfavorable prognosis.

Show MeSH
Related in: MedlinePlus